Black Diamond Therapeutics Income Statement (2018-2026) | BDTX

Income Statement Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
70.00M
Operating items
Research & Development (Quarter)
26.72M27.63M19.66M17.79M16.20M15.85M14.61M14.75M13.15M16.15M15.29M13.54M12.56M12.91M12.30M10.51M9.32M7.44M6.30M7.00M
Selling, General & Administrative (Quarter)
8.00M7.74M6.42M7.89M6.98M6.28M7.24M6.81M6.88M7.86M5.57M6.70M9.57M5.22M5.98M4.96M4.10M3.54M3.97M4.26M
Other Operating Expenses (Quarter)
7.35M
Operating Expenses (Quarter)
34.72M35.36M26.08M25.68M23.17M22.12M21.85M21.56M20.03M24.01M20.86M20.25M22.13M18.13M18.27M15.47M13.42M10.98M17.61M11.26M
Operating Income (Quarter)
-34.72M-35.36M-26.08M-25.68M-23.17M-22.12M-21.85M-21.56M-20.03M-24.01M-20.86M-20.25M-22.13M-18.13M-18.27M54.53M-13.42M-10.98M-17.61M-11.26M
EBIT (Quarter)
-34.72M-35.36M-26.08M-25.68M-23.17M-22.12M-21.85M-21.56M-20.03M-24.01M-20.86M-20.25M-22.13M-18.13M-18.27M54.53M-13.42M-10.98M-17.61M-11.26M
Non-operating items
Interest & Investment Income (Quarter)
0.95M0.78M0.59M0.41M0.39M0.56M0.68M0.62M0.54M0.44M0.32M0.64M0.46M0.52M0.56M0.59M1.12M1.16M1.18M1.02M
Other Non Operating Income (Quarter)
-0.58M-0.49M-0.38M-0.23M-0.14M-0.09M0.12M0.06M0.34M0.57M1.12M1.38M1.76M2.06M1.73M1.42M1.74M1.32M1.31M1.20M
Non Operating Income (Quarter)
0.36M0.29M0.21M0.17M0.24M0.47M3.02M0.69M0.88M1.00M1.45M2.02M2.22M2.57M2.29M2.01M2.86M2.48M2.49M2.22M
Net income details
EBT (Quarter)
-51.68M-43.00M-26.10M-25.98M-30.05M-57.27M-22.23M-21.99M-30.81M-55.06M-21.61M-20.69M-49.91M-24.98M-18.82M54.02M-12.89M-15.32M-17.57M-11.38M
Profit After Tax (Quarter)
-34.35M-35.15M-25.87M-25.51M-22.93M-21.65M-19.00M-20.88M-19.15M-23.01M-17.61M-18.23M-19.91M-15.56M-15.93M56.54M-10.56M-8.33M-15.12M-9.17M
Income from Continuing Operations (Quarter)
-51.68M-43.00M-26.10M-25.98M-30.05M-57.27M-22.23M-21.99M-30.81M-55.06M-21.61M-20.69M-49.91M-24.98M-18.82M54.02M-12.89M-15.32M-17.57M-11.38M
Consolidated Net Income (Quarter)
-51.68M-43.00M-26.10M-25.98M-30.05M-57.27M-22.23M-21.99M-30.81M-55.06M-21.61M-20.69M-49.91M-24.98M-18.82M54.02M-12.89M-15.32M-17.57M-11.38M
Income towards Parent Company (Quarter)
-51.68M-43.00M-26.10M-25.98M-30.05M-57.27M-22.23M-21.99M-30.81M-55.06M-21.61M-20.69M-49.91M-24.98M-18.82M54.02M-12.89M-15.32M-17.57M-11.38M
Net Income towards Common Stockholders (Quarter)
-51.68M-43.00M-26.10M-25.98M-30.05M-57.27M-22.23M-21.99M-30.81M-55.06M-21.61M-20.69M-49.91M-24.98M-18.82M54.02M-12.89M-15.32M-17.57M-11.38M
Additional items
EPS (Basic) (Quarter)
-1.43-1.19-0.72-0.72-0.83-1.58-0.61-0.60-0.84-1.08-0.49-0.40-0.90-0.44-0.340.95-0.23-0.27-0.31-0.20
EPS (Diluted) (Quarter)
-1.43-1.19-0.72-0.72-0.83-1.58-0.61-0.60-0.84-1.08-0.49-0.40-0.90-0.44-0.340.94-0.23-0.27-0.31-0.20
Shares Outstanding (Quarter)
36.18M36.22M36.19M36.27M36.29M36.35M36.33M36.48M36.52M50.94M43.95M51.81M55.16M56.51M55.03M56.66M56.80M56.93M56.87M57.23M
Shares Outstanding (Diluted) (Quarter)
36.18M36.22M36.19M36.27M36.29M36.35M36.33M36.48M36.52M50.94M43.95M51.81M55.16M56.51M55.03M57.67M56.80M56.93M57.56M57.23M
EBITDA (Quarter)
-34.72M-35.36M-26.08M-25.68M-23.17M-22.12M-21.85M-21.56M-20.03M-24.01M-20.86M-20.25M-22.13M-18.13M-18.27M54.53M-13.42M-10.98M-17.61M-11.26M
Interest Expenses (Quarter)
17.91M8.42M0.60M0.70M7.27M35.70M1.05M1.05M11.31M31.49M1.08M1.08M28.25M7.36M1.11M1.11M0.58M5.51M1.14M1.14M